Video-based long-term follow up of musician's dystonia in pianists reveals similar improvements following different treatment strategies: a retrospective observational study

Julius Gründahl  
Hanover University of Music Drama and Media Hannover

Michael Großbach  
University of Music, Drama, and Media Hannover

Eckart Altenmüller (✉ eckart.altenmueller@hmtm-hannover.de)  
University of Music, Drama and Media Hannover

Research article

Keywords: Musician's Dystonia, Video Rating, Botulinum-Toxin, Trihexyphenidyl, Retraining, Interrater Reliability, Therapy Response

DOI: https://doi.org/10.21203/rs.3.rs-364883/v1

License: ☭ ☘ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background Musician's Dystonia (MD) is characterised by impaired or complete loss of fine motor control in extensively trained movements at the instrument. In pianists, it frequently leads to involuntary flexion or extension of one or more fingers. Treatment remains challenging, although local injections with Botulinum toxin, anticholinergic medication and pedagogical retraining seem to be helpful in individual cases. Evaluation of therapies however is frequently hampered by lack of practicability, or validity. This retrospective observational study aims to assess the long-term development of MD and efficacy of therapies in keyboard players by means of a simple video-rating procedure by informed expert raters.

Methods Video rating was done by 6 carefully instructed pianists, rating a total of 266 videos from 80 patients, recorded over a period of almost 20 years. These showed the affected hand playing a C-major scale as “regularly” as possible at a moderate tempo on a grand piano. Raters assessed the acoustic irregularity of scale playing and any visible movement impairment on visual analogue scales. Influence of patient-specific factors including applied treatment was estimated in a Bayesian multilevel beta regression.

Results For ratings of irregularity and impairment intra-rater reliability was strong and inter-rater concordance was moderate. The average estimated improvement across all therapies was 14% in irregularity and 15% in impairment. Highest improvement rates in ratings of irregularity were found after the combined treatment with Botulinum toxin and Trihexyphenidyl (45%) as well as in retraining (29% improvement) as single therapy. In ratings of impairment the highest improvement was shown for retraining in combination with Trihexyphenidyl (36% improvement) as well as retraining as single therapy (23%).

Conclusions This study provides a new perspective on the course of MD in keyboard players in a larger cohort using methods other than self-report. Video rating of scale-playing was shown to be a reliable and useful method to evaluate MD in keyboard players. Average improvement rates were different to previous studies using patient-subjective questionnaires. Treatment options showed different effects in the two rating criteria, with retraining showing the highest improvement rates in single and combined use.

Background

Musician's Dystonia (MD), often termed musician's cramp, is a focal and task-specific form of dystonia affecting voluntary control of muscles or muscle groups used in highly precise and extensively trained movements while playing a musical instrument (1). Common symptoms are either impaired or complete loss of task-relevant voluntary motor control, leading to stiffness or cramping, the latter resulting in involuntary movements of affected fingers, i.e. flexion or extension (2, 3). According to rough estimations, one percent of all professional musicians are affected by MD, yet the dark number is probably higher (2, 4). MD has been described for almost every instrument group, with keyboard players being the most affected (5). Treatment options include symptomatic pharmacological treatment and pedagogical behavioural retraining techniques. In oral medication, the anticholinergic drug Trihexyphenidyl has been proven to be effective; nevertheless, frequent side effects such as dry mouth, fatigue and confusion have been reported, and a treatment effect has been shown only for limb dystonia (6, 7). EMG- or ultrasound-guided injection of botulinum toxin improves motor performance in a majority of patients but requires exact identification of the dystonic muscle and regular re-injections by an experienced clinician (8–11). As a behavioural therapy, pedagogical retraining has been introduced with the aim of restoring the disturbed cortical motor program. To this end, dystonic movements are identified, and then playing speed is slowed down to a level at which symptoms would not occur. Thus, compensatory movements are avoided. A correct movement pattern is
introduced, and the patient's awareness is trained by the use of visual feedback and body awareness techniques (12). Such a retraining requires a long therapeutic process and high intrinsic motivation by the patient, but also has shown sustained improvement of symptoms (12–14).

The long-term development of symptoms in MD has been described in several studies, using different assessment tools. Jabusch et al. (6), Schuele et al. (8) and van Vugt et al. (12) have mainly used patient-subjective questionnaires with ordinal scales, reporting an improvement in symptoms in 52%, 69% and 82% of the patients, respectively. As an objective evaluation method, MIDI-based scale playing analysis was introduced by Jabusch et al. in 2004 (15) and was additionally used in the study by van Vugt et al., revealing an improvement in 43% of the patients (12). For a subjective clinician rating, Spector and Brandfonbrener developed the Frequency of Abnormal Movements Scale, accounting for the frequency of dystonic flexion and compensatory extension movements while playing the instrument (16). However, although these objective assessments have been proven useful, they are time consuming, depend on technology and cannot be easily applied to other than pianistic movements. Therefore, there is still a need for standardized rating procedures approved in large, controlled studies (17). To our knowledge, so far there is no study describing the long-term development in a large patient cohort in a single instrument, without using patient-subjective rating instruments. In the following, we will present a retrospective, observational study assessing the long-term development of dystonic symptoms in keyboard players. The temporal development of symptoms was evaluated from video snippets recorded at the beginning and during or at the end of the treatment phase, introducing an informed rating procedure by piano-major students using visual analogue scales (VAS). The influence of several covariates, including the administered therapy, on the development of symptoms was evaluated in a Bayesian multilevel beta regression. Comprising 80 patients with clinical examinations performed between 1997 and 2016, it is so far the largest patient cohort with the longest observational period on focal dystonia in keyboard players.

Methods

As part of the examination at the outpatient clinic of the Institute of Music Physiology and Musicians’ Medicine Hanover over the last 25 years, most of the patients affected by MD were videotaped while playing their instrument. The recordings' main purpose was to objectively document the progression of the disorder for both clinicians and patients. The camera was usually placed to the right of the keyboard, capturing the patients' hands and forearms. Patients played up- and downwards C-major scales over two octaves, reportedly a difficult task for pianists with dystonic symptoms (15). This task requires not only very even and controlled movements of the five fingers, but also the difficult thumb-passage, i.e. the anticipatory flexion in ulnar-radial movements of the thumb under fingers 2–5, with no black keys involved. Since all classically educated pianists have been trained to play this scale as evenly and fast as possible, C-major scale playing has been identified as a highly automated, reliable, specific and sensitive measure of pianists' skills (18).

Video snippets of C-major scales were collected, and pianists suffering from MD with two or more such videos recorded at different time points were included in the study. All patients gave informed consent for recording and usage of the videos in the present study. Patient features other than hand or forearm were pixelated when visible in the video. Videos in which patients talked whilst playing were excluded. The study was approved by the ethics committee of the Hanover Medical School (Approval number 3690 – 2017).

Patient characteristics
Eighty patients (22 female) with a total of 266 videos, (median: 3, range: 2–12), were included in the study. The first video was recorded in September 1997, the last one in March 2016. The median time between the first and the last video for a single patient was 33 months (0–184). Owing to different playing tempi, videos had durations between 5 and 53 seconds (median 20). 73 patients were pianists, 6 were organists and one patient played harpsichord as their main instrument. All patients were diagnosed with focal dystonia by an experienced clinician and movement disorders specialist (EA), and 64 patients were found to be affected in the right hand and 14 in the left. In 2 patients affected in both hands, we decided to only rate the hand affected first in the course of the disorder. While at the onset of symptoms patients were a median of 31.5 years old (range: 18–68), by the time of the first recording patients had a median age of 37 years (21–71; two patients' files did not contain information about the onset of symptoms). The period between first symptoms and the first appointment at the clinic was between one and 480 months (median: 27). Therapy was mainly restricted to Botulinum-Toxin injections (BTX), Trihexiphenidyl (TRHX), retraining (RTR), or a combination thereof: 27 patients solely attended a retraining program, 10 patients only received BTX-injections and six were treated solely with TRHX; nine patients received a combination of BTX and RTR, and seven were administered a combination of either RTR and TRHX, or BTX and TRHX. 13 patients received a combination of all three therapies. One patient with only two videos included in the study received no treatment at all between the two appointments. Inclusion in therapy groups was independent from administered dose or treatment duration.

Patients were asked during the examination whether they were aware of relatives suffering from a movement disorder, which was confirmed by 6 patients (7.5%), whereas 57 answered in the negative (71.25%); for 17 patients (21.25%) there was no information available in the patient files. Patient data are also reported in Table 1.
| Number | Gender | Treatment duration | Age 1st symptoms | Time to treatment | Affected side | Affected finger(s) | Therapy       | Genetic predisposition |
|--------|--------|--------------------|------------------|------------------|--------------|-------------------|---------------|-----------------------|
| 1      | f      | 44                 | 40               | 50               | right        | 3                 | BTX, RTR      | n.a.                  |
| 2      | m      | 68                 | 23               | 12               | right        | Wrist, 2         | BTX, RTR, TRHX | -                     |
| 3      | m      | 31                 | 22               | 24               | left         | 2                 | BTX           | n.a.                  |
| 4      | m      | 38                 | 20               | 7                | right        | 3,4               | BTX, RTR, TRHX | -                     |
| 5      | f      | 49                 | 50               | 20               | right        | 4,5               | BTX, RTR, TRHX | -                     |
| 6      | m      | 10                 | 50               | 12               | right        | 3                 | BTX           | n.a.                  |
| 7      | m      | 16                 | 24               | 1                | right        | 3                 | RETR          | -                     |
| 8      | f      | 44                 | 24               | 6                | right        | 2,3               | RETR          | -                     |
| 9      | m      | 57                 | 37               | 60               | right        | 3                 | BTX, RTR, TRHX | +                     |
| 10     | f      | 22                 | 52               | 60               | right        | 4                 | BTX, RTR      | -                     |
| 11     | m      | 26                 | 33               | 5                | right        | 4                 | BTX, RTR, TRHX | -                     |
| 12     | f      | 84                 | 25               | 84               | right        | 1,2               | RETR          | -                     |
| 13     | m      | 43                 | 47               | 60               | right        | 2,3,4,5          | BTX, RTR      | -                     |
| 14     | m      | 30                 | 22               | 72               | right        | 4,5               | RTR           | -                     |
| 15     | m      | 68                 | 31               | 4                | right        | 3,4,5             | BTX, RTR      | -                     |
| 16     | m      | 42                 | 44               | 108              | right        | 1,3,4             | RTR, TRHX     | -                     |
| 17     | f      | 23                 | 28               | 12               | right        | 1                 | RETR          | -                     |
| 18     | f      | 7                  | 28               | 2                | left         | 4,5               | RTR           | -                     |
| 19     | m      | 24                 | 20               | 132              | right        | 3                 | BTX, RTR      | -                     |
| Number | Gender | Treatment duration | Age 1st symptoms | Time to treatment | Affected side | Affected finger(s) | Therapy | Genetic predisposition |
|--------|--------|--------------------|------------------|------------------|-------------|------------------|---------|------------------------|
| 20     | m      | 31                 | 39               | 264              | left        | 2,3,4            | BTX, RTR | -                      |
| 21     | f      | 46                 | 23               | 6                | left        | 2                | RTR     | n.a.                   |
| 22     | m      | 21                 | 33               | 156              | right       | 4,5              | BTX, TRHX | -                      |
| 23     | m      | 24                 | 40               | 12               | right       | 2,3,4            | RTR     | -                      |
| 24     | m      | 18                 | n.a.             | n.a.             | right       | 1,2,3,4,5       | BTX, RTR | +                      |
| 25     | f      | 6                  | 30               | 30               | right       | n.a.             | RTR, TRHX | -                      |
| 26     | m      | 56                 | 31               | 120              | right       | 3,4              | BTX     | -                      |
| 27     | f      | 8                  | 22               | 24               | right       | 3,4              | RTR     | -                      |
| 28     | m      | 48                 | 27               | 24               | right       | 3                | RTR     | -                      |
| 29     | f      | 25                 | 40               | 12               | right       | n.a.             | BTX, RTR, TRHX | -          |
| 30     | m      | 27                 | 37               | 24               | right       | n.a.             | RTR     | -                      |
| 31     | m      | 3                  | 29               | 36               | right       | 3                | RTR     | -                      |
| 32     | f      | 32                 | 29               | 276              | right       | 1,2              | RTR     | +                      |
| 33     | f      | 14                 | 24               | 9                | right       | 4,5              | RTR     | -                      |
| 34     | m      | 23                 | 20               | 48               | right       | 2                | RTR, TRHX | +                      |
| 35     | m      | 133                | 40               | 60               | right       | 3                | BTX, RTR, TRHX | n.a.      |
| 36     | m      | 30                 | 24               | 2                | right       | 4                | RTR     | -                      |
| 37     | m      | 95                 | 27               | 24               | right       | 3                | BTX, RTR, TRHX | -          |
| 38     | m      | 99                 | 46               | 36               | right       | 3                | BTX     | -                      |
| 39     | m      | 45                 | 37               | 8                | right       | 4,5              | RTR     | -                      |
| 40     | m      | 103                | 50               | 108              | right       | Wrist            | BTX, RTR, TRHX | -          |
| 41     | f      | 117                | 44               | 96               | right       | 3                | BTX, RTR, TRHX | -          |
| Number | Gender | Treatment duration | Age 1st symptoms | Time to treatment | Affected side | Affected finger(s) | Therapy | Genetic predisposition |
|--------|--------|--------------------|------------------|-------------------|--------------|-------------------|---------|-----------------------|
| 42     | f      | 72                 | 22               | 8                 | right        | Wrist             | RTR     | -                     |
| 43     | m      | 83                 | 24               | 8                 | right        | 2                 | RTR, TRHX | n.a.                 |
| 44     | m      | 34                 | 68               | 36                | right        | 3,4               | BTX     | n.a.                 |
| 45     | m      | 34                 | 39               | 36                | right        | 2,3,4             | none    | n.a.                 |
| 46     | m      | 87                 | 45               | 24                | right, left  | 3,4; 3            | TRHX    | -                     |
| 47     | m      | 27                 | 30               | 12                | right        | 3                 | RETR    | -                     |
| 48     | m      | 21                 | 48               | 12                | right        | 4,5               | BTX, RTR, TRHX | -     |
| 49     | m      | 34                 | 34               | 3                 | right        | 3                 | BTX, TRHX | -     |
| 50     | m      | 22                 | 31               | 72                | right        | 3,4,5             | BTX     | -                     |
| 51     | m      | 31                 | 33               | 72                | left         | 4                 | RTR     | -                     |
| 52     | m      | 117                | 63               | 36                | right        | 4,5               | BTX     | +                     |
| 53     | m      | 137                | 35               | 48                | left         | 2                 | BTX, TRHX | n.a.   |
| 54     | m      | 96                 | 27               | 240               | right, left  | 2,3,4; 3,4        | TRHX    | -                     |
| 55     | m      | 85                 | 29               | 96                | left         | n.a.              | TRHX    | -                     |
| 56     | m      | 36                 | 47               | 36                | right        | 3                 | RTR     | -                     |
| 57     | m      | 26                 | 27               | 132               | right        | 3,4               | BTX, TRHX | -     |
| 58     | m      | 59                 | 18               | 480               | left         | 1,2               | BTX, RTR | n.a.                |
| 59     | f      | 11                 | 28               | 9                 | left         | 3,4,5             | RTR     | n.a.                 |
| 60     | m      | 44                 | 28               | 12                | right        | 2,3               | BTX, TRHX | -     |
| 61     | f      | 19                 | 28               | 12                | right        | 3                 | RTR     | -                     |
| 62     | m      | 7                  | 61               | 132               | right        | 4,5               | RTR     | -                     |
| 63     | m      | 10                 | 29               | 72                | right        | 4,5               | RTR     | -                     |
| 64     | m      | 18                 | 56               | 9                 | right        | 2                 | RTR     | n.a.                 |
| 65     | m      | 39                 | 42               | 60                | left         | 4                 | RTR, TRHX | n.a.   |
| Number | Gender | Treatment duration | Age 1st symptoms | Time to treatment | Affected side | Affected finger(s) | Therapy | Genetic predisposition |
|--------|--------|--------------------|------------------|------------------|--------------|------------------|---------|-----------------------|
| 66     | f      | 14                 | 26               | 30               | left         | 2,4,5            | BTX, RTR | -                     |
| 67     | m      | 50                 | 39               | 12               | right        | 2,3              | BTX, RTR, TRHX | -                     |
| 68     | m      | 78                 | 32               | 144              | right        | 3,4              | BTX     | -                     |
| 69     | m      | 54                 | 28               | 72               | left         | 2,3,4,5          | BTX, RTR, TRHX | -                     |
| 70     | m      | 22                 | 44               | 6                | right        | 4,5              | RTR, TRHX | -                     |
| 71     | m      | 53                 | 29               | 12               | right        | 2,3,4            | BTX, TRHX | n.a.                  |
| 72     | f      | 15                 | 47               | 96               | right        | 3,4              | BTX, RTR, TRHX | n.a.                  |
| 73     | m      | 80                 | 21               | 12               | right        | 4,5              | BTX     | n.a.                  |
| 74     | m      | 31                 | 36               | 6                | left         | 3                | BTX, RTR, TRHX | -                     |
| 75     | m      | 0                  | 21               | 72               | left         | 2                | TRHX    | +                     |
| 76     | f      | 47                 | n.a.             | n.a.             | right        | 1                | TRHX    | n.a.                  |
| 77     | m      | 184                | 33               | 24               | right        | 3,4              | TRHX    | -                     |
| 78     | f      | 13                 | 35               | 6                | right        | 1,2,3            | BTX, TRHX | -                     |
| 79     | f      | 25                 | 34               | 12               | right        | 2,4              | BTX, RTR | -                     |
| 80     | m      | 5                  | 41               | 60               | right        | 3                | RTR     | -                     |

**Video rating**

Raters (n = 6, three female) were recruited from piano major classes at Hanover University of Music, Drama and Media. They received a two-hour introduction by a professional musician, neurologist and expert in MD (EA), explaining symptoms, risk factors and pathophysiology of MD. Furthermore, the rating process was thoroughly practiced with example videos not included in the study. The lab-based rating was supervised by one of the authors (JG).

Raters evaluated scale-playing videos on 10 cm visual analogue scales (VAS) (19), with 0 and 10 as anchor points (see Additional file 1). We aimed to evaluate acoustic as well as visual aspects of scale playing with the following two criteria: Temporal regularity of notes (very regular to very irregular at both ends of the “acoustic” VAS) and motor impairment of the movement (not impaired to highly impaired at both ends of the “visual” VAS). For the rating
of temporal regularity, raters were asked to evaluate the evenness of C-major scales by mainly paying attention to auditory information. For the rating of motor impairment, raters were instructed to identify the flexion of the dystonic finger(s) and the extension of the compensatory finger(s), a concept introduced by Candia et al. (19, 20) and further developed by Spector and Brandfonbrener (16). They were asked to rate the visual manifestation of these aberrant movements as an expression of muscular symptoms during scale playing.

For data analysis and presentation, we defined the VAS for irregularity such that high values represent very irregular and uneven scale playing. Raters provided a score for a video snippet with a vertical pencil stroke on the VAS line. A difference between two ratings in a given patient of, e.g. 1 cm on the VAS scale represented a difference of -1 or +1 in the rating criteria.

Each video was rated twice by a pair of raters, resulting in four ratings per video. For 266 videos included in the study, this amounted to a total of 1064 ratings. The rating process was split up into several sessions to reduce fatigue in raters. The videos were equally and randomly assigned to the six raters, so that each rater did not rate every video, but approximately 177 videos in four sessions distributed over four days within one week, with 44 to 45 videos per session in randomized order.

A movement disorders expert (author EA) also rated the videos in order to be able to compare them to the student raters' scores. Videos were again presented twice and in random order. In contrast to the student ratings however, the expert rating was not divided into clearly defined sessions for logistic reasons. Example videos from one patient included in the study are provided as additional file (see Additional file 2 and 3).

**Statistical analysis**

Rating scores for each video were calculated as the average of each rater and averaged across the pair of raters, separately for irregularity and impairment. The rating scores of the MD-expert were not included in this analysis.

To assess intra- and inter-rater reliability of the students' ratings, intra-class correlation (ICC) (21), average Pearson's product-moment correlation and inter-rater concordance coefficient (22) were calculated. For an evaluation of the expert rating, we computed the average of the two ratings for each video. Again, intra-rater reliability with Pearson's product-moment correlation and the inter-rater concordance coefficient were calculated to compare students and expert ratings.

To assess the temporal course of MD severity and the efficacy of the deployed therapies as well as the influence of patient-specific time factors (see below), we compared the rating scores of the first and last video available, omitting the ones in between, if any. By restricting the analysis to first and last videos we matched the number of observations per patient, considering that in 45% of the patients (n = 36) only two videos were available for the study. The omitted data will be presented elsewhere. Furthermore, for the main analysis we solely used the student ratings.

Data were subjected to Bayesian multilevel beta regression (23) with the irregularity and impairment rating scores of both videos as outcome after transformation of the original scores (between 0 and 10) to the range between 0 and 1. The outcome can be interpreted as ratio or percentage achieved of a possible maximum. Thus a (transformed) score of e.g. 0.65 is equivalent to 65% of the highest possible irregularity (or impairment). To assess the outcome at the two time points and to evaluate the influence of time point (first, last), treatment (retraining, Botulinum toxin injections, or Trihexyphenidyl medication) as well as treatment duration (in decades), time to treatment (time between first symptoms and treatment commencement; in decades) and age at first symptoms (in decades),
increasingly complex regression models were built, starting with the Null model, containing only the individuals as grouping structure. Then, step by step, additional explanatory variables were added. Explanatory variables containing missing data (i.e., \textit{time to treatment} and \textit{age at first symptoms}) were modelled such that the missing values were estimated using the entire information available (see Additional file 4 and 5 for modelling formulae). Finally, the resulting models were compared to each other by means of leave-one-out cross-validation (24), and only the best models were reported, unless noted otherwise (see Additional file 6 and 7). Model priors are reported in Additional file 4 and 5. All continuous input variables were centered to ease computation and interpretation.

\section*{Results}

\subsection*{Rating reliability}

Analysis of the intra-rater reliability of student ratings revealed a significant average Pearson's product moment correlation both for irregularity and impairment of \( r = 0.84 \) (95%-confidence interval \([0.81–0.86], p < 0.01\)) and a significant average ICC for irregularity of 0.86 (range: 0.83, 0.88) and for impairment of 0.88 (0.86, 0.90). The mean inter-rater concordance coefficient among students was \( r = 0.42 \) (0.05, 0.85) for irregularity ratings and \( r = 0.46 \) (0.14, 0.62) for impairment ratings. Intra-rater reliability was also significant in the expert rating, with correlation coefficients \( r = 0.7 \) ([0.64–0.76], \( p < 0.01 \)) for irregularity and \( r = 0.78 \) ([0.73–0.82], \( p < 0.01 \)) for impairment. The inter-rater concordance coefficient between students and expert was \( r = 0.43 \) [0.32–0.52] for irregularity and \( r = 0.48 \) [0.38–0.56] for impairment.

\subsection*{Data Exploration}

Figure 1 shows that non-random assignment to therapies led to varying sample sizes per therapy group and substantially differing group medians in rating scores prior to treatment.

Patients who received retraining as a single therapy formed the largest group and had the lowest pre-treatment scores for both irregularity and impairment in impairment together with the combination of Retraining and Trihexyphenidyl as single therapy.

\subsection*{Regression}

The best models with respect to expected log pointwise predictive density (elpd) (24) (see Additional file 6 and 7 for details on model comparison) for the outcomes irregularity and impairment contained in both cases no interactions for the population effects \textit{time point} and \textit{therapy}. Since this interaction was of special interest to answer the question of how large the impact of each therapy was over time on the two outcomes, we looked at those models with elpd values closest to the top model \textit{and} that included an interaction term. For both outcomes, these were the models also containing treatment duration as a covariate (see Additional file 6 and 7). The elpd values of both these models were less than two standard errors away from the respective best model and it was therefore deemed acceptable to consider them.

Across all therapies average relative improvements of 14\% in ratings of irregularity and 15\% in ratings of impairment were estimated (see Fig. 2A, B).

The results of the best irregularity model containing an interaction term for time and therapy (model m4airr in Additonal file 6) are presented in Table 2, whereas Table 3 shows the results of the best impairment model containing an interaction for time and therapy (model m4aimp in Additional file 7).
Only Botulinum toxin combined with Trihexyphenidyl (45% improvement), as well as retraining (29% improvement) alone yielded improvements such that 95% or more of the irregularity differences between T1 and T0 lay below zero; whereas in impairment, solely retraining alone (23% improvement) and retraining combined with Trihexiphenidyl (36% improvement) benefitted the patients to such a degree that 95% or more of the differences were located below zero (see Figs. 3A,B).

Table 2
Estimated mean irregularity scores at time points 0 and 1, the difference between the posterior distributions at both time points, the lower bound of the upper 95% of the difference distributions, and relative change between T0 and T1 for the eight therapy groups, as estimated by the best-fitting model with an interaction term (Therapy x Time). One patient (therapy: none) chose not to receive any treatment. See Table 1 for treatment abbreviations.

| Therapy      | Time 0 | Time 1 | Difference | LB of upper 95% | Rel. change |
|--------------|--------|--------|------------|-----------------|-------------|
| None         | 0.580  | 0.487  | -0.090     | 0.135           | 0.159       |
| BTX          | 0.502  | 0.486  | -0.015     | 0.129           | 0.032       |
| BTX_RTR      | 0.403  | 0.423  | 0.0201     | 0.172           | -0.049      |
| BTX_RTR_TRHX | 0.482  | 0.495  | 0.013      | 0.144           | -0.026      |
| BTX_TRHX     | 0.535  | 0.293  | -0.237     | -0.075          | 0.453       |
| RTR          | 0.385  | 0.275  | -0.10      | -0.025          | 0.286       |
| RTR_TRHX     | 0.407  | 0.350  | -0.057     | 0.108           | 0.139       |
| TRHX         | 0.583  | 0.459  | -0.1245    | 0.056           | 0.213       |
Table 3
Estimated mean impairment scores at time points 0 and 1 along with the difference between the posterior distributions at both time points, the lower bound (LB) of the upper 95% of the difference distributions, and relative (rel.) change between T0 and T1 for the eight therapy groups, as estimated by the best-fitting model with an interaction term (Therapy x Time). One patient (therapy: none) chose not to receive any treatment. See Table 1 for treatment abbreviations.

| Therapy   | Time 0 | Time 1 | Difference | LB of upper 95% | Rel. change |
|-----------|--------|--------|------------|-----------------|-------------|
| None      | 0.773  | 0.778  | 0.001      | 0.149           | -0.007      |
| BTX       | 0.637  | 0.571  | -0.064     | 0.077           | 0.104       |
| BTX_RTR   | 0.633  | 0.521  | -0.111     | 0.039           | 0.176       |
| BTX_RTR_TRHX | 0.667 | 0.621  | -0.046     | 0.068           | 0.069       |
| BTX_TRHX  | 0.616  | 0.526  | -0.089     | 0.081           | 0.146       |
| RTR       | 0.500  | 0.387  | -0.112     | -0.022          | 0.226       |
| RTR_TRHX  | 0.550  | 0.350  | -0.196     | -0.027          | 0.364       |
| TRHX      | 0.679  | 0.561  | -0.117     | 0.058           | 0.174       |

Discussion
This retrospective, observational study assessed the development of Musician's Dystonia in 80 keyboard players, and its dependence on patient specific factors with a rating procedure of videos recorded over a period of almost 20 years. Patient cohort characteristics are similar to other studies on MD, whose epidemiologic data has been reviewed by Conti et al. (25). The majority of patients were male, recognizing first symptoms of dystonia during their fourth decade of life. There was high variability in age at onset of symptoms, from early adulthood to retirement age. The right hand was predominantly affected and only a small number of patients presented symptoms in both hands. Our study has several limitations, due to its retrospective character and the fact that recording of videos took place during clinical examinations. Recordings were initially not intended to be used for a long-term study. Therefore, recording conditions were not standardized: no metronome was used, resulting in variable duration and tempo of scale playing; the camera angle with respect to the piano varied, with variable zoom settings. Furthermore, patients were not recorded at every visit, and recordings sometimes only took place when substantial changes of symptoms were apparent. The number of recordings per patient and the time between these recordings differed substantially, an effect we tried to minimize by only analysing the first and last video in every patient. In some videos, no C-major scales were played, which led to exclusion from the study, neglecting possibly valuable information. The retrospective character of this study meant that therapies were heterogeneously and not always continuously used due to the individual needs and preferences of each patient. This led to varying sample sizes between the different therapy groups.

Considering these limitations, the main findings of the study however, are informative. First, video rating with piano students as a homogeneous rater group using the scales explained above was a useful tool to retrospectively rate symptoms of MD in pianists. According to the Dystonia Study Group, a sufficient rating scale for the evaluation of dystonia (26), adapted for MD (17, 27), needs to measure MD specifically, be sensitive to change, be reliable and valid, as well as efficient and practical in clinical use. Our rating procedure is highly specific for rating MD in
pianists, by capturing the expression of symptoms (motor impairment of movement and temporal irregularity) during scale playing. The rating procedure used is also sensitive to change due to the use of visual analogue scales, which have been described as more sensitive in comparison to categorical Likert-Scales (28). Furthermore, analyses of rating reliabilities showed strong intra-rater reliability and moderate inter-rater concordance in student and expert ratings (classification according to Schober et al. (29)). One reason for the lower inter-rater concordance might be the different interpretation of the two rating criteria by the raters. Although we performed an introductory session with detailed explanations and training, irregularity and impairment are still subjective criteria with possibilities for individual interpretation. Nonetheless, lower inter-rater concordance between the expert and students can be explained by the different clinical background and experience and, combined with the strong intra-rater reliability in student raters thus supports the idea of a homogeneous rater group. The decision to choose piano students as raters was motivated by their group being rather homogenous with regard to age, own playing expertise, exposure to judging others’ playing abilities as well as medical expertise in MD, which we tried to impart during the training session.

Second, the relative average improvement across all therapies was 14% in ratings of irregularity and 15% in ratings of impairment, corresponding to an average change of -0.74cm and -0.92cm, respectively, on the visual analog scale. With the deployed methods we were to objectively verify a moderate improvement of MD symptoms in pianists over time. Van Vugt et al. also reported a tendency towards more regular scale playing in objective MIDI-analyses in pianists (12). Although the methods to calculate improvement rates differed, our study provides further evidence suggesting that therapy in MD in pianist has an objectively measurable positive effect on patients’ playing ability. Considering the fact that the data in our study and in the study by Van Vugt et al. were collected from overlapping time windows and from the same patient sample opens new possibilities for further studies by comparing the two data sets. Furthermore, it is noteworthy that ratios of quantitative improvement in objective rating in our study are substantially different from those in subjective rating in previous studies (e.g. 31% improvement in patient subjective questionnaires (12)). Van Vugt et al. stated the hypothesis that patients had the tendency to overestimate in a positive way the development of symptoms. This hypothesis can be supported by findings of Lee et al. reporting no difference in life satisfaction of patients with MD and healthy musicians. They assumed that patients with MD find a way to cope with dystonia regardless of the course of symptoms (30).

Third, therapies seem to show differing effects on treatment outcome. While Botulinum toxin in combination with Trihexyphenidyl showed the highest relative improvement in irregularity (45%, corresponding to an average improvement of 0.75cm; Table 2), the combination of retraining and Trihexyphenidyl showed the highest improvement in impairment (36%, equivalent to a change of -1.7cm; Table 3). The outcome of those patients receiving a combination of therapies has to be interpreted carefully though, considering the relatively small number of patients in the respective groups and the retrospective, observational design of this study as explained above. Unsuitable therapies were discontinued while other therapies were started in the treatment process for patients with an insufficient outcome in one therapy. For example, patients who chose to receive all three therapies might be characterized by a generally low treatment response and were thus possibly trying all available options, which in turn may explain the low effect on treatment outcome in the group BTX + RTR + TRHX. However, one might be surprised by the comparatively small effect of Botulinum toxin treatment alone (3% and 10% relative improvement in irregularity and impairment, respectively), contradicting self-report data by Schuele et al. which indicated a mild to marked improvement after therapy with Botulinum toxin in 69% of patients with MD (8). The low relative average improvement rate in our study might be explained by the fact that video recording took place during regular clinical examination and patients receiving injections with Botulinum toxin mostly asked for clinical appointments after deterioration of symptoms with the need for a new injection.
The fact that retraining was the most effective therapy fits into the results of previous studies comparing treatment effectiveness with subjective patient questionnaires. Van Vugt et al. reported that self-ratings attributed retraining a significantly stronger effect than Trihexyphenidyl, and Jabusch et al. reported an improvement in 50% of patients taking part in pedagogical retraining (6, 12).

Conclusions

In conclusion this study provides a new perspective on the course of Musician's Dystonia in keyboard players. The applied rating method showed sufficient intra-rater reliability and was efficient and useful by allowing rating of many patients in simple way, due to its intuitive use and the small number of rating criteria. We propose its use for a fast overview during regular clinical examination, though further validation is needed. We have shown positive treatment effects for all three commonly used therapeutic approaches, with clearest improvement following retraining therapy. However, since individual application of therapies according to life situation, the degree of impairment and personal demands of every patient guide diagnostic decisions, an individual approach remains crucial for the treatment.

List Of Abbreviations

BTX: Botulinum Toxin
EMG: Electromyography
MD: Musician's Dystonia
ICC: Intra-class correlation
RTR: Retraining
TRHX: Trihexyphenidyl
VAS: Visual Analogue Scale

Declarations

Ethics

The study was approved by the ethics committee of the Hanover Medical School (Approval number 3690-2017).

Consent for publication

Julius Gründahl, Michael Grossbach, and Eckart Altenmüller consent to publication

Competing interests

The authors declare that they have no competing interests

Availability of data and material
The videos, data and statistical algorithms are fully available in the Institute of Music Physiology and Musician's Medicine of the University of Music, Drama and Media upon request

Funding

The study was funded by the University of Music, Drama, and Media, Hannover

Authors contribution

Julius Gründahl designed the study, performed the experiment, evaluated the experiment and discussed the results and wrote the manuscript

Michael Grossbach designed the study, performed the statistical evaluation, discussed the results and wrote the manuscript

Eckart Altenmüller designed the study, collected the videos, evaluated and treated the patients, discussed the results, and wrote the manuscript.

Acknowledgements

The authors would like to thank Florian Worschech and Christos Ioannou for their invaluable comments and ideas during the planning phase of the study.

References

(1) Altenmüller E. Focal dystonia: advances in brain imaging and understanding of fine motor control in musicians. Hand Clin. 2003 Aug;19(3):523-38, xi. doi: 10.1016/s0749-0712(03)00043-x.

(2) Altenmüller E, Jabusch HC. Focal dystonia in musicians: phenomenology, pathophysiology and triggering factors. Eur J Neurol. 2010 Jul;17 Suppl 1:31-6. doi: 10.1111/j.1468-1331.2010.03048.x.

(3) Lederman RJ. Focal dystonia in instrumentalists: clinical features. Med Probl Perform Arti 1991;6(4):132-136.

(4) Lim VK, Altenmüller E, Bradshaw JL. Focal dystonia: current theories. Hum Mov Sci. 2001 Dec;20(6):875-914. doi: 10.1016/s0167-9457(01)00076-8.

(5) Altenmüller E, Baur V, Hofmann A, Lim VK, Jabusch HC. Musician's cramp as manifestation of maladaptive brain plasticity: arguments from instrumental differences. Ann N Y Acad Sci. 2012 Apr;1252:259-65. doi: 10.1111/j.1749-6632.2012.06456.x.

(6) Jabusch HC, Zschucke D, Schmidt A, Schuele S, Altenmüller E. Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Mov Disord. 2005 Dec;20(12):1623-6.

(7) Jankovic J. Medical treatment of dystonia. Mov Disord. 2013 Jun 15;28(7):1001-12. doi: 10.1002/mds.25552.

(8) Schuele S, Jabusch HC, Lederman RJ, Altenmüller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology. 2005 Jan 25;64(2):341-3. doi: 10.1212/01.WNL.0000149768.36634.92.

(9) Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995 Jul;10(4):466-71. doi: 10.1002/mds.870100411.
(10) Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand
dystonia. Neurology. 1994 Jan;44(1):70-6. doi: 10.1212/wnl.44.1.70.

(11) Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand
dystonia: outcome at 10 years or more. Mov Disord. 2011 Mar;26(4):750-3. doi: 10.1002/mds.23504.

(12) van Vugt FT, Boullet L, Jabusch HC, Altenmüller E. Musician's dystonia in pianists: long-term evaluation of
retraining and other therapies. Parkinsonism Relat Disord. 2014 Jan;20(1):8-12. doi:
10.1016/j.parkreldis.2013.08.009.

(13) Byl NN, McKenzie A. Treatment effectiveness for patients with a history of repetitive hand use and focal hand
dystonia: a planned, prospective follow-up study. J Hand Ther. 2000 Oct-Dec;13(4):289-301. doi: 10.1016/s0894-
1130(00)80021-6.

(14) Candia V, Wienbruch C, Elbert T, Rockstroh B, Ray W. Effective behavioral treatment of focal hand dystonia in
musicians alters somatosensory cortical organization. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7942-6. doi:
10.1073/pnas.1231193100.

(15) Jabusch HC, Vauth H, Altenmüller E. Quantification of focal dystonia in pianists using scale analysis. Mov
Disord. 2004 Feb;19(2):171-80. doi: 10.1002/mds.10671.

(16) Spector JT, Brandfonbrener AG. A new method for quantification of musician's dystonia: The Frequency of
Abnormal Movement Scale. Med Probl Perform Art 2005(25):157-162.

(17) Peterson DA, Berque P, Jabusch HC, Altenmüller E, Frucht SJ. Rating scales for musician's dystonia: the state of
the art. Neurology. 2013 Aug 6;81(6):589-98. doi: 10.1212/WNL.0b013e31829e6f72.

(18) van Vugt FT, Furuya S, Vauth H, Jabusch HC, Altenmüller E. Playing beautifully when you have to be fast:
spatial and temporal symmetries of movement patterns in skilled piano performance at different tempi. Exp Brain
Res. 2014 Nov;232(11):3555-67. doi: 10.1007/s00221-014-4036-4.

(19) Reips UD, Funke F. Interval-level measurement with visual analogue scales in Internet-based research: VAS
Generator. Behav Res Methods. 2008 Aug;40(3):699-704. doi: 10.3758/brm.40.3.699. PMID

(20) Candia V, Schäfer T, Taub E, Rau H, Altenmüller E, Rockstroh B, Elbert T. Sensory motor retuning: a behavioral
treatment for focal hand dystonia of pianists and guitarists. Arch Phys Med Rehabil. 2002 Oct;83(10):1342-8. doi:
10.1053/apmr.2002.35094.

(21) Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979
Mar;86(2):420-8. doi: 10.1037//0033-2909.86.2.420.

(22) Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989 Mar;45(1):255-68.

(23) Bürkner PC. Advanced Bayesian Multilevel Modeling with the R Package brms. The R Journal 2018;10(1):395-
411.

(24) Vehtari, A., Gelman, A. & Gabry, J. Practical Bayesian model evaluation using leave-one-out cross-validation and
WAIC. Stat Comput 2017;27;1413–1432 doi: 10.1007/s11222-016-9696-4
(25) Conti AM, Pullman S, Frucht SJ. The hand that has forgotten its cunning–lessons from musicians’ hand dystonia. Mov Disord. 2008 Jul 30;23(10):1398-406. doi: 10.1002/mds.21976.

(26) Rating scales for dystonia: assessment of reliability of three scales. Adv Neurol. 2004;94:329-36.

(27) Spector JT, Brandfonbrener AG. Methods of evaluation of musician's dystonia: critique of measurement tools. Mov Disord. 2007 Feb 15;22(3):309-12. doi: 10.1002/mds.21214.

(28) Flynn D, van Schaik P, van Wersch A. A comparison of Multi-Item Likert and Visual Analogue Scales for the Assessment of transactionally defined coping function. Eur J Psychol Assess 2004;20:49-58.

(29) Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. Anesth Analg. 2018 May;126(5):1763-1768. doi: 10.1213/ANE.0000000000002864.

(30) Lee A, Eich C, Ioannou CI, Altenmüller E. Life satisfaction of musicians with focal dystonia. Occup Med (Lond). 2015 Jul;65(5):380-5. doi: 10.1093/occmed/kqv038.

**Figures**

A

**Irregularity**

| Score | N = 1 | N = 10 | N = 9 | N = 13 | N = 7 | N = 27 | N = 7 | N = 6 |
|-------|-------|--------|-------|--------|-------|--------|-------|-------|

B

**Impairment**

| Score | 0 | BTX | BTX_RTR | BTX_RTR_TRX | RTR | RTR_TRX | TRX |
|-------|---|-----|---------|-------------|-----|---------|-----|

**Therapy**
Figure 1

Raw data of mean rating scores before treatment onset for seven different therapies and therapy combinations along with one patient who received no treatment. Each dot represents the mean VAS score of two ratings provided by two raters each on a given video snippet. A. Box-and-whisker plots of irregularity VAS-rating scores in the first video, i.e. before treatment commencement. B. Box-and-whisker plots of impairment VAS-rating scores in the first video. Note: rating scores were divided by ten for analytical reasons. 0, one patient without treatment; See Tab. 1 for treatment abbreviations.

Figure 2

Estimated rating scores of irregularity (A) and impairment (B) at T0 (first video) and T1 (last video) across all therapies, with points at the respective mean of the posterior distributions, and error bars showing the 95% credibility interval. Insets present the differences between the posteriors at both time points, with the red shaded areas designating the region between the upper 5% of the density mass and zero, with zero corresponding to no difference between the two time points.
Figure 3

Average estimated scores (with 95% credibility intervals) in student ratings at T0 (first video) and T1 (last video); A irregularity, and B impairment. See Tab. 1 for treatment abbreviations

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.png
- Additionalfile2.mp4
- Additionalfile3.mp4
- Additionalfile4.csv
- Additionalfile5.csv
- Additionalfile6.csv
- Additionalfile7.csv